---
title: "Cumberland Pharmaceuticals Inc. (CPIX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CPIX.US.md"
symbol: "CPIX.US"
name: "Cumberland Pharmaceuticals Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-19T19:27:34.414Z"
locales:
  - [en](https://longbridge.com/en/quote/CPIX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CPIX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CPIX.US.md)
---

# Cumberland Pharmaceuticals Inc. (CPIX.US)

## Company Overview

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H. pylori infection. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, aspirin-exacerbated respiratory disease, systemic sclerosis, and idiopathic pulmonary fibrosis.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.cumberlandpharma.com](https://www.cumberlandpharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: D (0.63)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 145 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 2.08% |  |
| Net Profit YoY | -125.33% |  |
| P/B Ratio | 3.54 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 76577930.24 |  |
| Revenue | 41939693.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -29.36% | E |
| Profit Margin | -17.60% | D |
| Gross Margin | 78.82% | A |
| Revenue YoY | 2.08% | C |
| Net Profit YoY | -125.33% | E |
| Total Assets YoY | 1.51% | C |
| Net Assets YoY | -24.83% | E |
| Cash Flow Margin | -19.25% | D |
| OCF YoY | 2.08% | C |
| Turnover | 0.60 | B |
| Gearing Ratio | 69.99% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Cumberland Pharmaceuticals Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "2.08%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-125.33%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.54",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "76577930.24",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "41939693.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-29.36%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-17.60%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "78.82%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "2.08%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-125.33%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "1.51%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "-24.83%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-19.25%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "2.08%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.60",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "69.99%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -10.39 | 191/190 | - | - | - |
| PB | 3.55 | 128/190 | 2.53 | 1.88 | 1.67 |
| PS (TTM) | 1.83 | 46/190 | 1.54 | 1.23 | 1.04 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2021-08-16T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 5.23 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CPIX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CPIX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CPIX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CPIX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**